Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated ...

Rabeprazole (Rabiprozole Sodium (20mg)) is a proton pump inhibitor, prescribed for duodenal ulcer, gastro esophageal reflux disease (GERD), and Zollinger-Ellison (gastric acid hyper secretion) ...

Rabeprazole is a proton pump inhibitor, prescribed for duodenal ulcer, gastro esophageal reflux disease (GERD), and Zollinger-Ellison (gastric acid hyper secretion) syndrome. It works by decreasing ...

Co announces that the FDA has granted final approval for the Company's Abbreviated New Drug Application for Rabeprazole Sodium Delayed-Release Tablets, 20 mg. TEVA's Rabeprazole Sodium Delayed-Release ...

March 13, 2007 — The US Food and Drug Administration (FDA) has approved first-time generic formulations for rabeprazole sodium 20-mg delayed-release tablets and ranitidine HCl 15-mg/mL oral ...

Lupin announced that its US subsidiary, Lupin Pharmaceuticals, Inc has launched its generic Rabeprazole Sodium delayed-release tablets, 20mg. Lupin had earlier received final approval from the US FDA ...